IONS Stock: Price, Earnings History and SEC Filings
Ionis Pharmaceuticals, Inc. (IONS) last traded at $43.52, down 1.96% on the latest session and down 2.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.70 against an analyst estimate of $-1.09, a beat of 35.8%.
$43.52 -1.96%
1 month-2.53%
52-week high$86.74
52-week low$42.08
Volume1.52M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IONS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $-0.70 | $-1.09 | +35.78% |
| Mar 2026 | Apr 29, 2026 | $-0.56 | $-0.89 | +37.08% |
| Dec 2025 | Feb 25, 2026 | $-1.41 | $-1.31 | -7.63% |
| Sep 2025 | Oct 29, 2025 | $-0.80 | $-1.23 | +34.96% |
IONS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for IONS
SEC filing data is not available right now. You can search for IONS on SEC EDGAR.
IONS news
- What Just Happened To Alnylam Stock?Oct 30, 2026 · trefis.com
- Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”Oct 29, 2026 · tikr.com
- ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseOct 29, 2026 · finance.yahoo.com
- Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues MissOct 27, 2026 · finance.yahoo.com
- Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)Oct 23, 2026 · finance.yahoo.com
- Ionis ranked #1 on Science’s Top Employers listOct 22, 2026 · finance.yahoo.com
- Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy TreatmentOct 22, 2026 · stocktwits.com
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (IONS) is a US-listed public company on Nasdaq.